References
- Eden OB, Lilleyman JS, Shaw MP, . Medical Research Council childhood leukemia trial VIII compared with trials II-VII: lessons for future management. Hematology and Blood Transfusions. Acute Leukemias, T Buchner, G Schellong, D Urbanitz, J Ritter, et al. Springer-Verlag, Berlin 1987; Vol. 30: 448–455
- Poplack DG. Acute lymphoblastic leukemia in childhood. The Leukemias, DG Poplack. WB Saunders, Philadelphia 1988; Vol. 35: 903–932
- Rhiem H, Gadner H, Henze G, . Udvikling of BFM. [Results and significance of six randomized trials in four consecutive ALL-BFM studies]. Haematology and Blood Transfusions. Acute Leukemias II, T Büchner, G Schellong, W Hiddemann, J Ritter, et al. Springer-Verlag, Berlin 1990; 439–450
- Poplack DG, Balis FM, Zimm S. The pharmacology of orally administered chemotherapy. Cancer 1986; 58: 473–480
- Schmiegelow K, Schrøder H, Pulczynska MK, Hejl M. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes. Cancer Chemother Pharmacol. 1989; 25: 65–69
- Schmiegelow K, Bruunshuus I. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia. Cancer Chemother Pharmacol. 1990; 26: 288–292
- Craft AW, Rankin A, Aherne W. Methotrexate absorption in children with acute lymphoblastic leukemia. Cancer Treat Rep. 1981; 65: 77–81, suppl. 1
- Koren G, Ferrazini Sulh H, et al. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Eng J Med. 1990; 323: 17–21
- Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989; 7: 1816–1823
- Schmiegelow K, Pulczynska MK, Seip M. White cell count during maintenance chemotherapy for standard-risk childhood acute lymphoblastic leukemia: relation to relapse rate. Pediatr Hematol Oncol. 1988; 5: 259–267
- Dolan G, Lilleyman JS, Richards SM. Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukemia. Arch Dis Child. 1989; 64: 1231–1234
- Hayder S. Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia. Thesis, T-tryk, Stockholm 1989
- Schmiegelow K, Pulczynska M. Maintenance therapy for childhood acute lymphoblastic leukemia: should dosage be guided by leukopenia?. Am J Pediatr Hematol Oncol. 1990; 12: 462–467
- Schmiegelow K, Pulczynska MK. Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Br J Cancer 1990; 61: 767–772
- Simon R, Wittes RE. Methodological guidelines for reports of clinical trials. Cancer Treat Rep. 1985; 69: 1–3
- Cox DR. Regression models and life-tables. J Roy Statist Soc B. 1972; 34: 187–202
- Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Statis Assoc. 1958; 53: 457–481
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. 1966; 50: 163–170
- Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980; 69: 585–594
- Hryniuk WM. Average relative dose intensity and the impact on clinical trials. Seminars in Oncology 1987; 14: 65–74
- Pinkel D, Hernandez K, Borella L, et al. Drug dosage and remission duration in childhood lymphoblastic leukemia. Cancer 1971; 37: 247–256
- Lennard L, Lilleyman JS, Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990; ii: 225–229